in111 monoclonal antibody bre-3
mAbexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 1997 (NCT00007891)
Timeline
1990s
- Jan 1, 1997
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Mucin-1Immunity, passive
MUC1 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- in111 monoclonal antibody bre-3
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00007891 | Phase 1 | Jun 1, 1997 | Cancer Research Institute of Contra Costa |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cancer Research Institute of Contra Costa | Academic/Hospital | 1 | 1 | 1 | 1997 |
1 organizations
Page 1 / 1